Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.36 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634707 | 0.85 | EPAS1 (0.47) | HSD11B1ALDH1A1SMN1; SMN2MAPK1EPAS1 | |
| SCHEMBL3493018 | 0.85 | HSD11B1 (0.46) | HSD11B1ALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL4773217 | 0.84 | PTGDR2 (0.55) | HSD11B1ALDH1A1SMN1; SMN2POLBPTGDR2 | |
| SCHEMBL3492576 | 0.84 | KMT2A (0.46) | HSD11B1ALDH1A1HTTMEN1POLB | |
| SCHEMBL13636835 | 0.84 | HSD11B1 (0.48) | HSD11B1ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL3491420 | 0.82 | HSD11B1 (0.50) | HSD11B1ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL3493327 | 0.80 | HSD11B1 (0.45) | HSD11B1PTGDR2EPAS1 | |
| SCHEMBL5666834 | 0.80 | CA12 (0.46) | MEN1KMT2AEPAS1 | |
| SCHEMBL14270838 | 0.78 | HSD11B1 (0.45) | HSD11B1ALDH1A1HTTSMN1; SMN2PTGDR2 | |
| SCHEMBL7498254 | 0.78 | PTGDR2 (0.49) | HSD11B1ALDH1A1SMN1; SMN2PTGDR2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403579-A | Novel spiro derivative and application thereof | 上海拓界生物医药科技有限公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-7378427-B2 | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | WYETH (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378427-B2 | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | WYETH (US) | 2008-05-27 | — | — | US | disclosed |
| CN-1968932-A | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | WYETH CORP (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1758866-A1 | PROCESSES FOR PREPARING 6-ALKYL-5-ARYLSULFONYL- DIHYDROPHENANTHRIDINES | Wyeth (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060025436-A1 | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | WYETH (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2006009831-A1 | PROCESSES FOR PREPARING 6-ALKYL-5-ARYLSULFONYL- DIHYDROPHENANTHRIDINES | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025436-A1 | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | QDPR, RPS9, RPS4Y1 | HSD11B1 4301/4885ALDH1A1 1238/4885HTT 513/4885 |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | HSD11B1 270/4885ALDH1A1 503/4885HTT 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.